Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Natan Ponieman

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) published encouraging data from a Phase II trial looking at ketamine-assisted therapy for the treatment of alcohol use disorder.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.